Toleranzia AB

The Swedish market will close at 13:00 on 2 April. The Norwegian and Danish markets will be closed on 2 April. On 3 and 6 April, the Swedish, Norwegian and Danish markets will be closed.

Toleranzia is a research company focused on the development of drug candidates for the treatment of autoimmune diseases. The company has developed a platform technology focused on the muscular disease myasthenia gravis. In addition, the technology has been used in other areas such as diabetes and multiple sclerosis. Research collaboration is done together with external partners within the field. The head office is based in Gothenburg.

Quotes for Toleranzia AB

+/-
%
()

Board

CEO

  • Charlotte Fribert

Chairperson of the Board

  • Anders Milton

Board

  • Anders Waas
  • Ann-Charlotte Rosendahl
  • Eva Lindgren
  • Jan Mattsson
  • Kristian Sandberg
  • Maarten Kraan
  • Articles of association

    • News

    Show More

    Analysis

    Videos

    Toleranzia - Stora Aktiedagen 4 november 2019

    Toleranzia förbereder industriell tillverkning och en fas 1/2a-studie

    Sedermeradagen Stockholm, 16 november 2017

    Stora Aktiedagen Göteborg, 14 november 2016

    Annual reports, prospectus etc.